Source comparison
Comparison: Melanotan-1 vs Alternative MC1R Agonists in Research
Before including the comparison table: Researchers evaluating melanogenesis tools face a trade-off between receptor specificity, stability, and translational relevance. The table below compares Melanotan-1 against endogenous α-MSH, the non-selective agonist ND
This comparison does not assign a generated winner or score.
- Before including the comparison table: Researchers evaluating melanogenesis tools face a trade-off between receptor specificity, stability, and translational relevance. The table below compares Melanotan-1 against endogenous α-MSH, the non-selective agonist NDP-MSH, and the longer-acting analogue Melanotan-2 across the parameters that determine research validity.
- | Agonist | MC1R Selectivity | Plasma Half-Life | Typical Research Dose | Primary Application | Stability Profile | Professional Assessment ||—|—|—|—|—|—|| Alpha-MSH (endogenous) | Moderate (10:1 MC1R:MC3R ratio) | 2–3 minutes | Not applicable. Degrades too rapidly for controlled dosing | Baseline reference for natural melanogenesis signalling | Unstable. Requires continuous infusion | Not viable for in vitro work due to enzymatic degradation || Melanotan-1 (afamelanotide) | High (1,000:1 MC1R selectivity) | 33 minutes | 10nM–100nM in vitro; 0.16mg/kg subcutaneous in vivo | Gold standard for MC1R-specific melanogenesis, photoprotection studies, vitiligo pathway research | Stable 28 days refrigerated post-reconstitution | The reference standard. Unmatched selectivity with validated dose-response reproducibility || NDP-MSH (synthetic pan-agonist) | Low (activates MC1R, MC3R, MC4R, MC5R equally) | 18 minutes | 1nM–10μM depending on target receptor | Broad melanocortin receptor screening |